Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer.
Introduction: Nivolumab combined with chemotherapy has been approved as the first-line treatment for HER2-negative, unresectable, advanced, or recurrent gastric cancer. Patients aged ≥75 years have impaired organ function and comorbidities that increase the risk of adverse events, including immune-r...
| Publicado en: | Oncology Vol. 104; no. 8; pp. 872 - 880 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Karger AG
2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195416404&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 195416404 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00302414 NK2 jtl: Oncology issn: 00302414 maglogo: N pubinfo: dt: 2026 vid: 104 iid: 8 pid: 2485 pub: Karger AG artinfo: ui: 195416404 191652602 195416404 195416404 10.1159/000550345 195416404 ppf: 872 ppct: 8 formats: tig: atl: Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer. aug: au: Kimura, Akiharu Sano, Akihiko Nakazawa, Nobuhiro Kumakura, Yuji Yamashita, Toshiki Tanaka, Naritaka Saito, Kana Ogata, Kyoichi Kasuga, Kengo Nakazato, Kenji Yoshinari, Daisuke Shimizu, Hisashi Ubukata, Yasunari Hosaka, Hisashi Okada, Takuhisa Shiraishi, Takuya Sakai, Makoto Shirabe, Ken Saeki, Hiroshi affil: Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan sug: subj: Stomach Neoplasms Drug Therapy Patient Safety Drug Efficacy Nivolumab Therapeutic Use Chemotherapy, Cancer Antineoplastic Agents, Combined Pharmacodynamics Neoplasm Recurrence, Local Drug Therapy Treatment Outcomes Human Male Female Aged Aged, 80 and Over Multicenter Studies Retrospective Design Record Review Immunotherapy Immune Checkpoint Inhibitors Body Weight Hypertension Incidence Overall Survival Hospitals Japan Japan Scales Descriptive Statistics Data Analysis Software T-Tests Wilcoxon Rank Sum Test Pearson's Correlation Coefficient Fisher's Exact Test Kaplan-Meier Estimator Survival Analysis Log-Rank Test Statistical Significance Aged: 65+ years Aged, 80 & over Male Female ab: Introduction: Nivolumab combined with chemotherapy has been approved as the first-line treatment for HER2-negative, unresectable, advanced, or recurrent gastric cancer. Patients aged ≥75 years have impaired organ function and comorbidities that increase the risk of adverse events, including immune-related adverse events more often than younger patients, potentially limiting the continuation of treatment. In this multicenter study, we aimed to evaluate the safety and efficacy of first-line nivolumab chemotherapy in older patients. Methods: We retrospectively analyzed data from 103 patients treated with first-line nivolumab combination chemotherapy for unresectable, advanced, or recurrent gastric cancer at 12 institutions between November 2021 and January 2023. The participants were divided into groups A (<75 years, n = 67) and B (≥75 years, n = 36). Results: The mean age was 63.9 years in Group A and 78.6 years in Group B. Body weight was significantly lower (p = 0.041), and performance status 0–1 and hypertension were more prevalent in Group B (both p < 0.01). Chemotherapy regimens and incidence of grade ≥3 immune-related adverse events were similar between the groups. The median overall survival was 15.2 months in Group A and was not reached in Group B; this difference was not significant (p = 0.689). Conclusions: First-line chemotherapy with nivolumab is safe and effective in patients aged ≥75 years with a good performance status, as in younger patients, suggesting that it is a valid treatment option for the former subgroup. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|